Case report: Slipped capital femoral epiphysis: a rare adverse event associated with FGFR tyrosine kinase inhibitor therapy in a child

• DOI: 10.3389/fonc.2024.1399356
• Publication Date: 2024-05-24T04:44:28Z
• Authors: Meziane Brizini; Tina Drimes; Catherine Bourne; Jessica Streilein; Annie Drapeau; Jens Wrogemann; Lori Anne Archer; Marc Del Bigio; Magimairajan Issa...
• Keywords: Discontinuation

We report a case of slipped capital femoral epiphysis (SCFE), an on target skeletal toxicity pan-FGFR TKI inhibitor, erdafitinib. A 13-year-old boy was diagnosed to have optic pathway/hypothalamic glioma with signs increased intracranial pressure and obstructive hydrocephalus requiring placement ventriculo-peritoneal (VP) shunt. Sequencing the tumor showed FGFR1-tyrosine kinase domain internal tandem duplication (FGFR1-KD-ITD). He developed hypothalamic obesity rapid weight gain BMI >30. At 12 weeks treatment erdafitinib, he persistent knee pain. X-ray right hip SCFE. Erdafitinib discontinued, underwent surgical pinning hip. MRI at discontinuation erdafitinib 30% decrease in size tumor, which has remained stable 6 months follow-up. Our experience literature review suggest that pediatric patients who are treated TKIs should be regularly monitored for side effects.